Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- No Activity0–2
- Mild Activity3–4
- Moderate Activity5–10
- High Activity11–19
The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) calculates classifying inflammatory arthritides and monitoring longitudinal autoimmune disease activity. Key inputs include seizure. Scores guide initiating or optimizing disease-modifying antirheumatic drugs (DMARDs) or targeted biologic therapies. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies severity of systemic lupus erythematosus (SLE) based on 24 clinical and laboratory parameters, allowing documentation of persistent disease activity.
Clinical Indication
The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) is indicated for bedside clinical practice to support Stratifies severity of systemic lupus erythematosus (SLE) based on 24 clinical and laboratory parameters, allowing documentation of persistent disease activity.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with inflammatory arthritis, systemic lupus erythematosus, systemic vasculitis, or autoimmune connective tissue disorders. Clinical application is indicated across Rheumatology clinics, connective tissue disease units, and academic medical centers.
Limitations & Contraindications
Elevated erythrocyte sedimentation rate (ESR) and CRP are non-specific acute phase reactants that can reflect occult systemic infection.
Clinical Pearls & Action Plan
Serological autoantibody testing must strictly correlate with inflammatory joint patterns and objective synovial pathology.
Sum of weighted scores for 24 items (8 points for CNS/vascular, 4 points for renal/musculoskeletal, 2 points for serositis/dermatologic/immunologic, 1 point for constitutional/hematologic)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| seizure | string | Yes | Recent onset seizure (exclude metabolic, infectious, or drug causes) |
| psychosis | string | Yes | Altered mental function with impaired reality perception (exclude uremia, drugs) |
| organic_brain_syndrome | string | Yes | Altered mental function with impaired cognition, memory, or concentration |
| visual_disturbance | string | Yes | Retinal changes of SLE (cytoid bodies, retinal hemorrhages, exudates, hemorrhage in choroid or optic neuritis) |
| cranial_nerve_disorder | string | Yes | New onset sensory or motor neuropathy involving cranial nerves |
| lupus_headache | string | Yes | Severe persistent headache, may be migrainous, nonresponsive to narcotic analgesia |
| cva | string | Yes | New onset cerebrovascular accident (stroke) |
| vasculitis | string | Yes | Ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy/angiogram proof |
| arthritis | string | Yes | ≥2 joints with pain and signs of inflammation (tenderness, swelling, or effusion) |
| myositis | string | Yes | Proximal muscle aching/weakness with elevated CPK/aldolase or EMG changes or biopsy showing myositis |
| urinary_casts | string | Yes | Heme-granular or red blood cell casts |
| hematuria | string | Yes | >5 RBCs/high power field (exclude stone, infection, or other causes) |
| proteinuria | string | Yes | New onset or recent increase >0.5 g/24 hours |
| pyuria | string | Yes | >5 WBCs/high power field (exclude infection) |
| rash | string | Yes | New or ongoing inflammatory type rash |
| alopecia | string | Yes | New or ongoing abnormal patchy or diffuse hair loss |
| mucosal_ulcers | string | Yes | New or ongoing oral or nasal ulcerations |
| pleurisy | string | Yes | Pleuritic chest pain with pleural rub, effusion, or pleural thickening |
| pericarditis | string | Yes | Pericardial pain with rub, effusion, or ECG/echo confirmation |
| low_complement | string | Yes | Decreased C3, C4, or CH50 below normal lab limits |
| increased_dna_binding | string | Yes | Increased anti-dsDNA antibody binding above normal range |
| fever | string | Yes | Temperature >100.4°F (38°C) excluding infection |
| thrombocytopenia | string | Yes | Platelets <100 × 10⁹/L excluding drug causes |
| leukopenia | string | Yes | WBC <3 × 10⁹/L excluding drug causes |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | No Activity | No disease activity |
| 3–4 | Mild Activity | Mild disease activity |
| 5–10 | Moderate Activity | Moderate disease activity |
| 11–19 | High Activity | High disease activity |
| 20–105 | Very High Activity | Very high disease activity |
Evidence-Based References (EBM)
- Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.
- Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62.
- Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 2010 Jan;19(1):49-51. doi: 10.1177/0961203309346505.DOI: 10.1177/0961203309346505
Related calculators
- Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
- Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP)
- Disease Activity Score-28 for Rheumatoid Arthritis with ESR (DAS28-ESR)
- Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis
- ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria